Relyvrio

green light shining in night
Biotech

FDA lifts clinical hold on Amylyx ALS trial

The trial represents Amylyx's latest effort in ALS after last year’s market withdrawal of Relyvrio.
Gabrielle Masson Jan 21, 2025 10:35am
walk away maze enter challenge puzzle decision

Amylyx CEOs take hard lessons to rebuild the pipeline

Jul 10, 2024 7:00am
rare diseases

Amylyx stock slips 6% after phase 2 rare disease data drop

Apr 10, 2024 2:48pm